OvaScience
Cambridge
Massachusetts
United States
Tel: 617-902-0682
Website: http://www.ovascience.com/
Email: info@ovascience.com
171 articles about OvaScience
-
Millendo Therapeutics Announces Successful Merger Completion with OvaScience, Inc
12/7/2018
Merger with OvaScience Closed
-
Shareholders raise concern over the fairness of the reverse merger and question potential conflicts of interest of OvaScience's co-founder.
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing
11/1/2018
– New Commitment by Great Point Partners Brings Proceeds of Transactions to $87 Million –
-
OvaScience Reports Second Quarter 2018 Financial Results and Provides Strategic Alternatives Update
8/9/2018
OvaScienceSM reported financial results for the second quarter ended June 30, 2018 and provided an update on its review of strategic alternatives.
-
Beleaguered OvaScience is Absorbed in Reverse Merger by Michigan-based Millendo Therapeutics
8/9/2018
Shares of struggling OvaScience have dipped 8 percent this morning after the company announced it entered into an all-stock reverse merger agreement with privately-held Millendo Therapeutics, Inc. of Ann Arbor, Mich. -
OvaScience Reports First Quarter 2018 Financial Results and Provides Business Update
5/3/2018
OvaScienceSM reported financial results for the first quarter ended March 31, 2018 and provided a business update.
-
OvaScience Reports Fourth Quarter and Year-End 2017 Financial Results
3/15/2018
OvaScience reported financial results and provided a business update for the fourth quarter and year ended December 31, 2017.
-
Pfizer Quits Neuroscience R&D
1/8/2018
As a result, the company will cut 300 jobs, primarily in Massachusetts and Connecticut. -
OvaScience provided a corporate update that includes initial data from a Phase I trial and news of extensive layoffs.
-
OvaScience Reports Third Quarter 2017 Financial Results
11/3/2017
As of September 30, 2017, OvaScience had cash, cash equivalents and short-term investments of $75.7 million, compared to $114.4 million as of December 31, 2016.
-
OvaScience to Host Third Quarter 2017 Financial Results Conference Call
10/27/2017
OvaScience announced today that it will host a conference call at 4:30 p.m. ET on Thursday, November 2, 2017 to discuss third quarter 2017 financial results and provide a general corporate update.
-
OvaScience Reports Second Quarter 2017 Financial Results
8/4/2017
-
OvaScience To Host Second Quarter 2017 Financial Results Conference Call
7/27/2017
-
OvaScience Slashes 50% of Workforce, Replaces CEO
6/23/2017
-
OvaScience Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)
6/22/2017
-
OvaScience Completes Enrollment Of 70 Patients In Ovaprime Clinical Study In Women With Primary Ovarian Insufficiency Or Poor Ovarian Response
6/13/2017
-
OvaScience Reports First Quarter 2017 Financial Results
5/10/2017
-
OvaScience To Host First Quarter 2017 Financial Results Conference Call
5/3/2017
-
OvaScience Reports Fourth Quarter And Year-End 2016 Financial Results
3/3/2017